Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 4/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.34 |
| ▸ | CCR2 | P41597 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14170373 | 0.96 | CCR2 (0.36) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL14170002 | 0.88 | CHRM5 (0.37) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL14170161 | 0.87 | ACHE (0.40) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL14170172 | 0.86 | CCR2 (0.38) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL14170163 | 0.86 | ACHE (0.42) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL14170268 | 0.86 | ACHE (0.42) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL14170405 | 0.86 | CHRM5 (0.36) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL14170228 | 0.85 | FPR2 (0.34) | ACHE | |
| SCHEMBL14170921 | 0.85 | CCR2 (0.33) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL14170129 | 0.85 | ACHE (0.37) | CHRM5CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390801-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070203108-A1 | Alzheimer's disease; 5-{N'-(4-thianaphthenacetyl)-L-alaninyl}-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one | THORSETT EUGENE D | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203108-A1 | Alzheimer's disease; 5-{N'-(4-thianaphthenacetyl)-L-alaninyl}-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one | APP, BACE1, PSEN1 | CHRM5 336/4885CHRM2 1330/4885CHRM4 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.